Bioxcel Therapeutics — Financial Results
IGALMI Sales Collapsed as the Company Pulled Back Commercial Support
| Metric | 2025 | 2024 |
|---|---|---|
| IGALMI net revenue | $642K | $2,266K |
| Cost of goods sold | $164K | $2,143K |
| Inventory write-down charges | $108K | $1,980K |
IGALMI (the company's only approved product) saw sales fall 72% year-over-year. This was a deliberate choice — the company gutted its sales and marketing team through a series of "Clinical Reprioritizations" (planned workforce and spending cuts) in 2024, shedding 9 marketing and sales employees as recently as September 2024. The focus has shifted away from hospital sales and toward getting IGALMI approved for home use, which the company sees as a much larger opportunity.
An sNDA for At-Home Use Is the Company's Central Bet Right Now
The Phase 3 SERENITY At-Home trial met its primary safety goal in August 2025 and showed positive exploratory efficacy data in September 2025. On January 14, 2026, the company filed a supplemental New Drug Application (sNDA) — a request to expand an already-approved drug's label — with the FDA to allow patients to self-administer IGALMI at home without a healthcare provider present. There are currently no FDA-approved options for this setting, which would represent a meaningfully larger market than supervised hospital use.
The Company Has a Serious Cash Runway Problem
| Metric | Value |
|---|---|
| Cash on hand (Dec 31, 2025) | $28.8M |
| Net loss (2025) | $69.9M |
| Cash burned in operations (2025) | $57.6M |
| Estimated runway | Into Q2 2026 |
Management has explicitly flagged "substantial doubt" about the company's ability to continue as a going concern (meaning it may not survive the next 12 months without new money). At the current burn rate, cash on hand covers only a few months of operations. The company is actively seeking equity sales, partnerships, and debt restructuring to stay afloat.
The Debt Load Is Heavy and the Lender Has Significant Control
The company carries $112 million in debt under a Credit Agreement with tight covenants (rules the borrower must follow). The lender has repeatedly had to waive defaults — most recently in March 2026 via a Ninth Amendment — including waivers for the going concern qualification in the auditor's report. Under the latest terms, the company must hand over 50% of any new capital raised directly to the lender as debt repayment (above the first $2.5 million). This significantly limits how much new fundraising actually helps the company's day-to-day operations.
Costs Are Down Sharply, But Mostly Due to Headcount Cuts — Not Efficiency
| Expense | 2025 | 2024 | Change |
|---|---|---|---|
| Selling, general & administrative | $20.5M | $34.5M | -41% |
| R&D | $30.3M | $30.4M | -1% |
Selling, general and administrative (SG&A) costs dropped $14 million, almost entirely because the company laid off a large portion of its staff. R&D spending was essentially flat — personnel costs fell, but clinical trials expense jumped 64% (from $9.4M to $15.4M) due to the SERENITY At-Home trial. The company is spending more on its pipeline drug even as it shrinks everywhere else.
The Company Has Been Diluting Shareholders to Raise Cash
To keep the lights on, BioXcel has issued large amounts of new stock. In 2025 alone, it raised $34.5 million by selling shares through an "at the market" (ATM) program — continuously selling small amounts of stock into the open market. It also completed a March 2025 registered direct offering raising ~$13 million and a March 2026 offering raising ~$7.8 million. The company also executed a 1-for-16 reverse stock split in February 2025, consolidating shares to avoid being delisted. Frequent share issuances reduce the ownership percentage of existing shareholders.